WEBINAR: A New Gentle Model of Neuropathic Pain
By using the new biomimetic model of neuropathic pain, your preclinical program can replace the Chung model, discover how opiates act over time and explore targeted biologics.
NeuroDigm Corp. was founded to translate clinical experience treating neuropathic pain into a preclinical research and development program. NeuroDigm’s program focuses on neuropathic pain as a tissue matrix disorder in the development of biomimetic animal models for analgesic screening. NeuroDigm has general nonexclusive licenses for the nonsurgical NeuroDigm GELTM Model in various rodents and provides instruction to licensees. This webinar introduces the only rodent model of chronic neuropathic pain, as seen in patients.
This webinar will enable the participant to:
- Define the difference between acute, subacute and chronic neuropathic pain.
- Recognize the biological tissue repair process causing chronic neuropathic pain.
- Justify the replacement of the Chung model, to help define your neural target.
- Assess the NeuroDigm GELTM Model translational value in opioid resistance and in the targeted use of biologics.
Featured Speaker:
Mary Hannaman, MD
President and Founder
Neurodigm
Mary Hannaman, MD is the physician founder and president of NeuroDigm Corp. She has over thirty years of active clinical experience with the treatment of neuromuscular injuries, spinal cord injuries, amputations, neurological disorders, and degenerative conditions.
She has expertise in targeted therapeutic nerve blocks, and her clinical focus is on the neuroanatomic diagnosis and localized treatment of subacute and chronic pain conditions associated with these disorders.
Brought to you by Arrowhead Publishers, the organizers of the:
Register now to view the replay of this FREE webinar